BPS804 Anti‐Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial

@article{Glorieux2017BPS804AA,
  title={BPS804 Anti‐Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial},
  author={Francis H. Glorieux and J. P. Devogelaer and Michaela Durigova and Stefan Goemaere and Sarah Hemsley and Franz Jakob and Uwe Junker and Jon L. Ruckle and Lothar Seefried and Peter J. Winkle},
  journal={Journal of Bone and Mineral Research},
  year={2017},
  volume={32}
}
This 21‐week, open‐label, phase 2a trial aimed to evaluate the pharmacodynamics and safety of multiple, escalating infusions of BPS804, a neutralizing, anti‐sclerostin antibody, in adults with moderate osteogenesis imperfecta (OI). Patients received BPS804 (three escalating doses each separated by 2 weeks [5, 10, and 20 mg/kg]) or no treatment (reference group). The primary efficacy endpoints were mean changes from baseline to day 43 in: procollagen type 1 N‐terminal propeptide (P1NP… 
Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy
  • L. NicolYing Wang E. Orwoll
  • Medicine, Biology
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2018
TLDR
Sclerostin regulation is fundamentally altered in osteogenesis imperfecta; serum SOST levels could be a biomarker of OI in adults; and alterations in SOST may help predict the response to anabolic therapies in OI.
Low Dose of Bisphosphonate Enhances Sclerostin Antibody‐Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model
TLDR
Preclinical results support the scientific hypothesis that minimal antiresorptive treatment can amplify the effects of SclAb during early stages of skeletal growth to further improve bone structure and rigidity, a beneficial outcome for children with OI.
Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin.
TLDR
Available data of both agents with regard to efficacy and safety as well as their possible future application are discussed, and abaloparatide was FDA approved in April 2017 is discussed.
Targeting TGF-β for treatment of osteogenesis imperfecta
TLDR
Increased TGF-β signaling is a driver pathogenic mechanism in OI, and anti–TGF- β therapy could be a potential disease-specific therapy, with dose-dependent effects on bone mass and turnover.
Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application
TLDR
An outlook comprising future translational applications of anti-sclerostin antibodies in diseases other than osteoporosis is given, highlighting the clinical significance and future scopes of Wnt signaling in these settings.
Sclerostin Antibody Treatment Stimulates Bone Formation to Normalize Bone Mass in Male Down Syndrome Mice
TLDR
SclAb stimulated bone formation and increased osteoblastogenesis without affecting osteoclastogenesis or bone resorption, and these data suggest that SclAb is a promising new therapy to improve bone mass and reduce fracture risk in the face of the low bone Mass and turnover prevalent in the DS population.
Romosozumab: a novel bone anabolic treatment option for osteoporosis?
TLDR
In Japan, South Korea, Canada, Australia, and the USA, osteoporosis patients at a high risk of fracture may already be treated with romosozumab (Evenity), and Approval in the European Union was granted by 2019-12-12.
Cardiovascular Safety and Sclerostin Inhibition - a mini-review.
TLDR
While there is no preclinical or genetic evidence of a harmful effect of sclerostin inhibition on cardiovascular safety, the evidence from the large clinical trials in postmenopausal women is conflicting and romosozumab should be used for the treatment of post menopausal women with osteoporosis at high risk of fracture after careful consideration of the cardiovascular risk and the balance between benefits and risks.
Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis
TLDR
Sclerostin (SOST), a glycoprotein produced by osteocytes, is an extracellular Wnt antagonist that blocks the binding of Wnt ligands to Lrp5/6, preventing the activation of the pathway and osteoblast-mediated bone formation subsequently, and represents a new therapeutic paradigm for the treatment of osteoporosis.
MANAGEMENT OF ENDOCRINE DISEASE: Osteogenesis imperfecta: an update on clinical features and therapies.
TLDR
Clinically, OI is heterogeneous in features and variable in severity, and new strategies are being explored, such as sclerostin inhibitory antibodies and TGF beta inhibition, to address not only the low bone mineral density but also the inherent bone fragility.
...
...

References

SHOWING 1-10 OF 44 REFERENCES
Romosozumab in postmenopausal women with low bone mineral density.
TLDR
In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption.
Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta.
TLDR
The benefits of cyclic infusions of ibandronate to children with OI are significant because ib andronate could significantly reduce annual bone fracture rate, increase lumbar and hip BMD, preserve vertebral morphometry of patients through inhibition of bone resorption.
Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta
TLDR
Short‐term Scl‐Ab was successfully anabolic in osteoblasts harboring a typical OI‐causing collagen mutation and represents a potential new therapy to improve bone mass and reduce fractures in pediatric OI.
Intravenous Neridronate in Adults With Osteogenesis Imperfecta
  • S. AdamiD. Gatti L. Tatò
  • Medicine, Biology
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2003
TLDR
Neridronate iv infusions, administered quarterly, significantly increase bone mineral density and lowered the risk of clinical fracture in adults with OI.
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
TLDR
In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months.
Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength
TLDR
Treatment of adult OI mice respond favorably to sclerostin antibody therapy despite retention of the OI-causing defect, and a strong anabolic response to Scl-Ab led to improved trabecular and cortical bone mass in the femur.
Bone Mineral Density and Fracture Rate in Response to Intravenous and Oral Bisphosphonates in Adult Osteogenesis Imperfecta
TLDR
A need to consider whether bisphosphonate treatment is appropriate for all adults with OI is appropriate, and results underscore a need for further research into this issue.
The Effect of Intravenous Pamidronate on Bone Mineral Density, Bone Histomorphometry, and Parameters of Bone Turnover in Adults with Type IA Osteogenesis Imperfecta
TLDR
It is indicated that intravenous pamidronate, 30 mg every 3 months, may have significant effects on bone density and histomorphometry in adults with type IA OI.
Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial
TLDR
In this double-blind randomised placebo-controlled trial it was investigated during a two-year follow-up whether oral bisphosphonates influence quality of life in children with osteogenesis imperfecta whether Olpadronate 10 mg/m2/day or placebo, finding only slight differences in quality oflife in favour of the bisph phosphonate group.
...
...